Drug & intervention
sulindac
RxCUI 10237
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Sulindac
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed as Clinoril. Imbaral is another name for this drug. Its name is derived from sul(finyl)+ ind(ene)+ ac(etic acid) It was patented in 1969 and approved for medical use in 1976.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
4 shownNSAID Effects on Clinical and Imaging Breast BiomarkersNCT01761877 · 2012-12-01
COMPLETEDSulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial DysplasiaNCT00368927 · 2006-08-01
COMPLETEDSulindac in Preventing Breast Cancer in Women at High Risk for Breast CancerNCT00245024 · 2005-11-01
COMPLETEDSulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast CancerNCT00039520 · 2002-01-01
COMPLETEDConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.